Competitive Landscape : If approved, CT-388 would likely join other GLP-1 receptor agonists and various combination therapies on the market
Ingredients: Deionized Water (Aqua),Glycerin,Sodium Hyaluronate (Hyaluronic Acid), Hydrolyzed Marine Collagen,Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7 (Matrixyl 3000), Acetyl Hexapeptide-8 (Argireline), DL-Panthenol (Vitamin B5), Beta Glucan,Copper Tripeptide-1(GHK-Cu),sh-Oligopeptide-1(EGF),Tetrasodium EDTA,Cichorium Intybus Extract(Chicory Root Extract),Phenoxyethanol-Ethylhexylglycerin(Euxyl PE 9010),PolyglutamicAcid
Patients should be aware that: No licensed combination product exists in the UK Any combination use would be considered experimental and is not supported by current evidence Clinical decisions must be guided by a qualified healthcare professional with access to current trial data Clinical Evidence and Trial Data Available to UK Patients Retatrutide Phase 2 data showed approximately 24% mean body weight reduction at the highest dose over 48 weeks, but no published trial data exist for the specific cagrilintideretatrutide combination
some experience no joint symptom change despite weight loss, suggesting metabolic or inflammatory phenotypes that don't respond primarily to weight reduction
Because carnitine levels are known to be low in patients receiving these drugs, scientists sought to determine whether supplements would offset these effects.32 In a 2004 study, acetyl-L-carnitine supplementation produced improvement in an impressive 76% of patients suffering from neuropathy related to HIV/AIDS medications.32 Unfortunately, many HIV patients discontinue their lifesaving medications because of the painful side effect of neuropathy
